MYX
Delivery · High$197M—
Mayne Pharma Group
Specialty pharmaceuticals
Specialty pharma focused on dermatology and women's health in the US market
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$197M
Burn Rate
—
Shares Outstanding
81M
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther5 June 2026
Mayne Pharma receives $14.4m for legal costs from Cosette
Mayne Pharma received $14.4 million from Cosette Pharmaceuticals in payment of legal costs, interest, and costs associated with its application, following a Supreme Court of New South Wales order dated 29 May 2026. This payment represents recovery of costs from Mayne Pharma's successful legal proceedings against Cosette regarding the termination of a Scheme Implementation Deed, with the Court delivering judgment in favour of Mayne Pharma in October 2025. Cosette has appealed the October 2025 judgment, with the appeal hearing completed on 2-3 June 2026 and decision reserved.
3M Price
MYX.ASX$2.410+0.4% 3M
Low $2.130High $2.870
Pipeline Assets (3)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Substantial Holders (5%+ threshold)
4 noticesCEASEDCitigroup Global Markets Australia Pty Limited and related bodies corporate in the Citi group of companies worldwide
CEASEDCitigroup Global Markets Australia Pty Limited
INITIALCitigroup Global Markets Australia Pty Limited and related bodies corporate in the Citigroup group of companies worldwide
Catalysts (6)· 3 upcoming · 3 past
RHOFADE generic competition entry
UpcomingConfirmedarrow_upwardHigh30 June 2026
Expectedarrow_upwardHigh30 June 2026
US HRT black box warning removal — BIJUVA/IMVEXXY impact
UpcomingExpected
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
High75/100(limited data)
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 3 of 3 guided dates· rolling 2yr· of 6 tracked
What drove these scores · rolling 2yr
·
Court awards MYX $13.27m for legal costs from Cosette — Delivered on time
·
New DistributeRx partnership with Resilia Pharmaceuticals — Delivered on time
·
Mayne Pharma receives $14.4m for legal costs from Cosette — Delivered on time
·
Limited data adjustment — Score adjusted toward neutral (3/6 data points) — accuracy improves with more completed catalysts
Completed catalysts
✓Court awards MYX $13.27m for legal costs from Cosette— Mayne Pharma has been awarded $13.27 million in legal costs by the Supreme Court of New South Wales following its successful October 2025 judgment against Cosette Pharmaceuticals regarding termination of a scheme implementation deed. The court has ordered Cosette to pay the costs plus interest, with further orders on interest amount and payment timeframe expected shortly.
On time
✓New DistributeRx partnership with Resilia Pharmaceuticals· partnership — counterparty-driven— Mayne Pharma's DistributeRx subsidiary will exclusively distribute Resilia Pharmaceuticals' RECEDO® topical gel through its prescription distribution platform in the United States, receiving a fixed fee per prescription filled.
On time
✓Mayne Pharma receives $14.4m for legal costs from Cosette— Mayne Pharma received $14.4 million from Cosette Pharmaceuticals in payment of legal costs, interest, and costs associated with its application, following a Supreme Court of New South Wales order dated 29 May 2026. This payment represents recovery of costs from Mayne Pharma's successful legal proceedings against Cosette regarding the termination of a Scheme Implementation Deed, with the Court delivering judgment in favour of Mayne Pharma in October 2025. Cosette has appealed the October 2025 jud
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
No active trials
Announcements(16)
article
OtherPSauto_awesome
Mayne Pharma receives $14.4m for legal costs from Cosette5 June 2026
expand_more152KB
handshake
Partnershipauto_awesome
New DistributeRx partnership with Resilia Pharmaceuticals31 May 2026
expand_more152KB